News - Bayer

Filter

Current filters:

Bayer

Popular Filters

50 to 74 of 308 results

Bayer CEO calls for greater appreciation of innovation

Bayer CEO calls for greater appreciation of innovation

19-11-2013

Advances in cancer therapy are expected in the next years, thanks in particular to treatment using antibody-drug…

BayerNephrology and HepatologyOncologyPharmaceuticalResearchRespiratory and Pulmonary

EU approval for Bayer’s prostate cancer drug Xofigo

EU approval for Bayer’s prostate cancer drug Xofigo

15-11-2013

The European Commission has granted marketing authorization for German drug and chemical major Bayer’s…

AlgetaBayerEuropeOncologyPharmaceuticalRegulationXofigo

Liver cancer market to nearly treble in size to $1.4 billion by 2019

Liver cancer market to nearly treble in size to $1.4 billion by 2019

13-11-2013

The value of the hepatocellular cancer (HCC) market is set to grow by a massive 172% and hit $1.4 billion…

BayerEuropeMarkets & MarketingNexavarNorth AmericaOncologyOnyx PharmaceuticalsPharmaceuticalResearchUSA

Eylea filed for EU and US approval in diabetic macular edema

Eylea filed for EU and US approval in diabetic macular edema

07-11-2013

US biotech firm Regeneron Pharmaceuticals says its partner German drug major Bayer has submitted an application…

BayerDiabetesEuropeEyleaNorth AmericaOphthalmicsPharmaceuticalRegeneronRegulation

Morningstar analysts find GlaxoSmithKline has strongest pipeline

Morningstar analysts find GlaxoSmithKline has strongest pipeline

06-11-2013

Morningstar, an independent Chicago-based investment research firm, recently published the November 2013…

AbbVieAstraZenecaBayerFinancialGlaxoSmithKlineMerck & CoPharmaceuticalResearchSanofi

Regeneron 3rd-qtr beats expectations, as total revenues leap 40%

Regeneron 3rd-qtr beats expectations, as total revenues leap 40%

06-11-2013

US biotech firm Regeneron Pharmaceuticals has posted financial and operating results for the third quarter…

BayerBiotechnologyEyleaFinancialOphthalmicsRegeneron

Strong 3rd-qtr quarter for Bayer as profits soar

Strong 3rd-qtr quarter for Bayer as profits soar

31-10-2013

German pharma and chemical major Bayer this morning presented third-quarter 2013 financial results, showing…

BayerFinancialPharmaceutical

Asia-Pacific region macular degeneration market to see modest growth; report

Asia-Pacific region macular degeneration market to see modest growth; report

30-10-2013

Due to the absence of promising products in the pipeline or expected new drug launches, the macular degeneration…

Asia-PacificBayerEyleaLucentisMacugenMarkets & MarketingNovartisOphthalmicsPfizerPharmaceuticalRegeneronRoche

Bayer HealthCare appoints Olivier Brandicourt as new CEO

Bayer HealthCare appoints Olivier Brandicourt as new CEO

30-09-2013

Bayer this morning revealed that Olivier Brandicourt has been appointed chairman of the board of management…

BayerEuropeManagementPharmaceutical

Bayer’s Eylea primary endpoint in two Phase III trials for DME

Bayer’s Eylea primary endpoint in two Phase III trials for DME

27-09-2013

Bayer (BAYN: DE) this morning said that Eylea has achieved the primary endpoint in two pivotal phase…

BayerEuropeEyleaOpthalmicsPharmaceuticalRegeneronResearch

Bayer gains two orphan drug designations for riociguat

Bayer gains two orphan drug designations for riociguat

26-09-2013

Bayer’s investigational drug riociguat has been granted two orphan drug designations by the US Food…

BayerNorth AmericaPharmaceuticalRegulationRespiratory and Pulmonaryriociguat

MSF warns of US/Indian tension over generic policy discussion

MSF warns of US/Indian tension over generic policy discussion

25-09-2013

Humanitarian group Médecins Sans Frontières has warned that India is facing political pressure from…

Anti-viralsAsia-PacificBayerGenericsGleevecHealthcareNexavarNorth AmericaNovartisPolitics

Phase III pooled EINSTEIN studies reaffirm Bayer's Xarelto role for venous thromboembolism

Phase III pooled EINSTEIN studies reaffirm Bayer's Xarelto role for venous thromboembolism

22-09-2013

Data from the Phase III EINSTEIN clinical trial program published Friday in the Thrombosis Journal underline…

BayerCardio-vascularPharmaceuticalResearchXarelto

EMA unit backs approval of Bayer's radium-233

EMA unit backs approval of Bayer's radium-233

20-09-2013

The European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended…

AlgetaBayerEuropeOncologyPharmaceuticalradium-223 dichlorideRegulationXofigo

KYTHERA submental fat drug candidate meets all primary endpoints in Ph III

17-09-2013

US biotech firm KYTHERA Biopharmaceuticals (Nasdaq: KYTH) saw its stock upgraded to $50 a share from…

ATX-101BayerDermatologicalsKYTHERA BiopharmaceuticalsPharmaceuticalResearch

Approved cancer drug potentially could help treat diabetes, Stanford researchers find

16-09-2013

A pair of studies by researchers at the Stanford University School of Medicine has identified a molecular…

afliberceptBayerBiotechnologyDiabetesEyleaOncologyPharmaceuticalRegeneronResearchSanofiZaltrap

Bayer joins string of drugmakers being investigated in China

16-09-2013

German pharma and crop sciences major Bayer (BAYN: DE) is being investigated in China over a "potential…

Asia-PacificBayerLegalMarkets & MarketingPharmaceutical

Bayer enters a further academic collaboration on innovative cancer therapies

10-09-2013

In a further collaboration with academia, German pharma and chemical major Bayer (BAYN: DE) has entered…

BayerLicensingOncologyPharmaceuticalResearch

Bayer links with DKSH to expand in Singapore

10-09-2013

DKSH Business Unit Healthcare, a leading partner for health care companies seeking to grow their business…

Asia-PacificBayerMarkets & MarketingPharmaceutical

Germany's Bayer plans to boost sales in Russia by 80% by 2017

06-09-2013

German pharmaceutical, material and crop sciences major Bayer's (BAYN: DE) chief executive Marijn Dekkers…

BayerFinancialMarkets & MarketingPharmaceutical

Bayer files for EU approval of regorafenib for GIST

05-09-2013

German pharma major Bayer (BAYN: DE) said this morning (September 5) that it has submitted an application…

BayerEuropeOncologyOnyx PharmaceuticalsPharmaceuticalregorafenibRegulationStivarga

50 to 74 of 308 results

Back to top